Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06154200 · ClinicalTrials.gov registry record · Phase 2
Eyelid Androgen Treatment in Dry Eye
A Phase 2 study, sponsored by Southern California College of Optometry at Marshall B. Ketchum University.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT06154200: Completed Phase 2 study, sponsored by Southern California College of Optometry at Marshall B. Ketchum University.
NCT06154200 is a Phase 2 study that has completed, run by Southern California College of Optometry at Marshall B. Ketchum University. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06154200, a Phase 2 study, has completed, sponsored by Southern California College of Optometry at Marshall B. Ketchum University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the effectiveness and safety of applying androgen sex hormone (i.e., testosterone) gel on the eyelids in the treatment of dry eye patients. Several studies have demonstrated positive treatment effects in dry eye, but few have applied testosterone gels to the eyelids.
Primary Outcome
Time to first dark spot appearance in the tear film
Interventions
- DRUG Vehicle gel
- DRUG Testosterone gel 4.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-04-02 |
| Est. Completion | 2024-05-30 |
| Phase | Phase 2 |
What the finished NCT06154200 record still lists
NCT06154200 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle gel is the first listed.
NCT06154200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06154200 about?
NCT06154200 is a clinical study titled "Eyelid Androgen Treatment in Dry Eye". The purpose of this research study is to evaluate the effectiveness and safety of applying androgen sex hormone (i.e., testosterone) gel on the eyelids in the treatment of dry eye patients. Several studies have demonstrated positive treatment effects in dry eye, but few have applied testosterone gel...
What is the current status of trial NCT06154200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2023-04-02. Estimated completion is 2024-05-30.
What interventions are being tested in trial NCT06154200?
The interventions under investigation include: Vehicle gel (DRUG), Testosterone gel 4.5% (DRUG).
Who is sponsoring clinical trial NCT06154200?
This trial is sponsored by Southern California College of Optometry at Marshall B. Ketchum University, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06154200's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI